
|Articles|February 4, 2013
FDA Challenges Stem Cell Companies As Patients Run Out Of Time
Advertisement
Americans seeking stem cell replacement therapy hope the process can heal them of myriad diseases, and a 2011 report by the Baker Institute estimated the industry could bring in $16 billion in revenue by 2020.
But the Food and Drug Administration has expressed concerns. The agency sued to stop treatments at a Regenerative Sciences clinic in Colorado and closed the lab of another company, Celltex Therapeutics, in Texas.
Read the full story:
Source: NPR
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
3
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
4
New Proteomic Analysis Maps Cytokine Signatures Driving IPF
5














































